Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, Marrano P, da Cunha Santos G, Lagarde A, Richardson F, Seymour L, Whitehead M, Ding K, Pater J, Shepherd FA. Tsao MS, et al. Among authors: lorimer i. N Engl J Med. 2005 Jul 14;353(2):133-44. doi: 10.1056/NEJMoa050736. N Engl J Med. 2005. PMID: 16014883 Free article. Clinical Trial.
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Goss G, Hirte H, Miller WH Jr, Lorimer IA, Stewart D, Batist G, Parolin DA, Hanna P, Stafford S, Friedmann J, Walsh W, Mathews S, Douglas L, Seymour LK. Goss G, et al. Among authors: lorimer ia. Invest New Drugs. 2005 Mar;23(2):147-55. doi: 10.1007/s10637-005-5860-y. Invest New Drugs. 2005. PMID: 15744591 Clinical Trial.
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.
Mackenzie MJ, Hirte HW, Glenwood G, Jean M, Goel R, Major PP, Miller WH Jr, Panasci L, Lorimer IA, Batist G, Matthews S, Douglas L, Seymour L. Mackenzie MJ, et al. Invest New Drugs. 2005 Mar;23(2):165-70. doi: 10.1007/s10637-005-5862-9. Invest New Drugs. 2005. PMID: 15744593 Clinical Trial.
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, Winquist E, Laurie S, Hayes DN, Dancey JE, Brown S, Pond GR, Lorimer I, Daneshmand M, Ho J, Tsao MS, Siu LL. Agulnik M, et al. Among authors: lorimer i. J Clin Oncol. 2007 Sep 1;25(25):3978-84. doi: 10.1200/JCO.2007.11.8612. J Clin Oncol. 2007. PMID: 17761983 Clinical Trial.
Stage-dependent differential expression of microRNAs in colorectal cancer: potential role as markers of metastatic disease.
Vickers MM, Bar J, Gorn-Hondermann I, Yarom N, Daneshmand M, Hanson JE, Addison CL, Asmis TR, Jonker DJ, Maroun J, Lorimer IA, Goss GD, Dimitroulakos J. Vickers MM, et al. Among authors: lorimer ia. Clin Exp Metastasis. 2012 Feb;29(2):123-32. doi: 10.1007/s10585-011-9435-3. Epub 2011 Nov 26. Clin Exp Metastasis. 2012. PMID: 22120473
Repression of cancer cell senescence by PKCι.
Paget JA, Restall IJ, Daneshmand M, Mersereau JA, Simard MA, Parolin DA, Lavictoire SJ, Amin MS, Islam S, Lorimer IA. Paget JA, et al. Among authors: lorimer ia. Oncogene. 2012 Aug 2;31(31):3584-96. doi: 10.1038/onc.2011.524. Epub 2011 Nov 28. Oncogene. 2012. PMID: 22120720
BRCA1 protein levels and PIK3CA mutations as predictive biomarkers for response to neoadjuvant chemotherapy in locally advanced breast cancer: An exploratory analysis.
Hilton J, Weberpals J, Lorimer I, Amin S, Islam S, Pelletier L, Daneshmand M, Hanson J, Nabavi M, Parolin D, Mallick R, Verma S. Hilton J, et al. Among authors: lorimer i. Oncol Lett. 2012 Jul;4(1):141-145. doi: 10.3892/ol.2012.697. Epub 2012 Apr 26. Oncol Lett. 2012. PMID: 22807977 Free PMC article.
62 results